| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/06/2004 | US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders |
| 05/06/2004 | US20040086896 Polynucleotides and polypeptides associated with the NF-kB pathway |
| 05/06/2004 | US20040086887 Comprises cytochrome p450 polypeptide for diagnosing, preventing and treating metabolic, autoimmune, inflammatory, cell proliferative, developmental, vision, liver and gastrointestinal disorders |
| 05/06/2004 | US20040086884 Using gene-targeted double stranded RNA (dsRNA) to inhibit preferential gene expression in cells; targeted tissue gene therapy |
| 05/06/2004 | US20040086882 Comprises nucleotide sequences coding mutant multidrug resistance gene (MDR) which confers side effect reduction to anticancer drugs |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086876 Methods for detecting mutations associated with hypertrophic cardiomyopathy |
| 05/06/2004 | US20040086875 Novel proteins and nucleic acids encoding same |
| 05/06/2004 | US20040086863 Comprises pleckstrin homology domain-interacting protein (PHI Protein) for identifying modulator and treatment for cancer and insulin response disorders |
| 05/06/2004 | US20040086857 Proliferative glomerular nephritis-associated gene |
| 05/06/2004 | US20040086854 Drug metabolizing enzymes |
| 05/06/2004 | US20040086848 Comprises polypeptide for modulating bone loss via inhibition of osteoclast precursor cell fusion; treatment and prevention of bone disorders |
| 05/06/2004 | US20040086845 Nucleotide sequences coding fusion protein comprising translocation domain for targeting and treating tumors; antitumor agents |
| 05/06/2004 | US20040086581 Bio-energetic joint and arthritis pain formula |
| 05/06/2004 | US20040086578 Physiologically acceptable aqueous solutions and methods for their use |
| 05/06/2004 | US20040086571 For therapy of dyslipidemia and dyslipoproteinemia |
| 05/06/2004 | US20040086557 Polyethylene glycol coated Pokeweed Mitogen and Recombinant Interleukin II |
| 05/06/2004 | US20040086556 Transdermal and topical administration of local anesthetic agents using basic enhancers |
| 05/06/2004 | US20040086535 The use of anti-viral peptides for the reduction of virus infectivity and treatment of viral infection |
| 05/06/2004 | US20040086534 Method of decreasing the severity or frequency of a relapse of multiple sclerosis |
| 05/06/2004 | US20040086532 Mucoadhesive nanoparticulate systems, including liposomes and polymeric nanoparticles |
| 05/06/2004 | US20040086531 Botulinum toxin oral formulation, wherein carrier is formulated to release therapeutic amounts in a gastrointestinal tract of a patient with a gastric ulcer without a significant immune system response |
| 05/06/2004 | US20040086529 Vaccines containing ribavirin and methods of use thereof |
| 05/06/2004 | US20040086528 Capable of inhibiting the fusion of HIV-1 to CD4+ cells and thus of inhibiting HIV-1 infection of the cells |
| 05/06/2004 | US20040086521 Method for the identification of antigenic peptides |
| 05/06/2004 | US20040086519 P-selectin antagonism inhibits cellular adhesion, e.g., platelet-leukocyte adhesion at site of vascular injury, inhibits neointimal formation, and modulate vascular remodeling |
| 05/06/2004 | US20040086518 Universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
| 05/06/2004 | US20040086516 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 05/06/2004 | US20040086515 Modified in such a way that its half-life in the vascular compartment is prolonged |
| 05/06/2004 | US20040086514 Based on the finding of a specific Helicobacter pylori receptor in the human gastric epithelium; a glycolipid, lactotetraosylceramide, exclusively found in the human gastrointestinal tract |
| 05/06/2004 | US20040086512 Multimerization of HIV-1 VIF protein as a therapeutic target |
| 05/06/2004 | US20040086511 Neuronal gene expression patterns |
| 05/06/2004 | US20040086510 Binds to insulin responsive aminopeptidase or GLUT4 glucose transporter 4 therapeutic agent for treatment or prophylaxis of hyperglycemia or diabetes |
| 05/06/2004 | US20040086509 Enhancing sperm motility wherein a Zins2 testis- specific insulin homolog polypeptide is added to sperm, an egg, an egg-sperm mixture, prior to fertilization |
| 05/06/2004 | US20040086502 Has a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for said antigen |
| 05/06/2004 | US20040086501 Protein having activity as an angiogenesis modulator |
| 05/06/2004 | US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV |
| 05/06/2004 | US20040086498 Cancer therapy |
| 05/06/2004 | US20040086497 Cell-matrix structure for implantation stably expressing a gene encoding at least one biological modifier to stop or regress excessive tissue proliferation |
| 05/06/2004 | US20040086494 Immune privileged cells for delivery of proteins and peptides |
| 05/06/2004 | US20040086493 That can be polymerized in contact with living cells and tissues, and in a very short time period that can be polymerized in contact with living cells and tissues, and in a very short time period. |
| 05/06/2004 | US20040086487 Prevention or the treatment of congestive heart failure or myocardial ishchemia by administering a sphingosine kinase, or an analogue, fragment, or derivative thereof |
| 05/06/2004 | US20040086484 Beta interferon for the treatment of chronic spinal cord injury |
| 05/06/2004 | US20040086462 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086461 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086458 Radio-opaque polymer biomaterials |
| 05/06/2004 | EP1416282A2 Method for screening compounds for treating bone disorders |
| 05/06/2004 | EP1416046A1 Use of histamine receptor h3 gene in controlling body weight or food intake |
| 05/06/2004 | EP1415998A2 Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| 05/06/2004 | EP1415995A2 Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| 05/06/2004 | EP1415994A1 Retinal pigmented epithelium derived neurotrophic factor |
| 05/06/2004 | EP1415669A1 Process for sterilization of protein containing biological compositions |
| 05/06/2004 | EP1415668A1 Remedies for brain ischemic diseases |
| 05/06/2004 | EP1415664A1 Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds |
| 05/06/2004 | EP1415663A1 Sustained release hgf hydrogel preparations |
| 05/06/2004 | EP1415662A1 Homing autologous cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415661A1 Homing of embryonic stem cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415660A1 Homing donor cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/06/2004 | EP1415641A1 Oxidating creme in form of an oil-in-water emulsion for treating human keratin fibres |
| 05/06/2004 | EP1415154A2 Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors |
| 05/06/2004 | EP1415006A2 Assay for identifying inhibitors of hiv rt dimerization |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1414999A1 Antisense modulation of acyl coenzyme a cholesterol acyltransferase-1 expression |
| 05/06/2004 | EP1414996A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 05/06/2004 | EP1414992A2 Method for identifying compounds modulating sister chromatid separation |
| 05/06/2004 | EP1414984A2 Nucleic acid encoding polypeptide involved in cellular entrance of the prrs virus |
| 05/06/2004 | EP1414983A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/06/2004 | EP1414974A2 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| 05/06/2004 | EP1414965A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/06/2004 | EP1414964A2 Vegf isoform |
| 05/06/2004 | EP1414963A2 Lipid-associated molecules |
| 05/06/2004 | EP1414961A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 05/06/2004 | EP1414959A1 Delivery of dsrna to arthropods |
| 05/06/2004 | EP1414954A2 Epsti1, a gene induced by epithelial-stromal interaction in human breast cancer |
| 05/06/2004 | EP1414946A2 Dendritic cells and the uses thereof in screening cellular targets and potential drugs |
| 05/06/2004 | EP1414866A2 Fgf-affinity chromatography |
| 05/06/2004 | EP1414864A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/06/2004 | EP1414863A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/06/2004 | EP1414856A2 Modified calcitonin |
| 05/06/2004 | EP1414855A2 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 05/06/2004 | EP1414852A2 Human secreted proteins, their encoding pulynucleotides, and uses thereof |
| 05/06/2004 | EP1414851A2 Cellular virus receptors and methods of use. |
| 05/06/2004 | EP1414849A2 Immune-modulating peptide |
| 05/06/2004 | EP1414847A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/06/2004 | EP1414846A2 Molecule |
| 05/06/2004 | EP1414845A2 Human secreted proteins |
| 05/06/2004 | EP1414842A2 Antisense modulation of acyl coa cholesterol acyltransferase-2 expression |
| 05/06/2004 | EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use |
| 05/06/2004 | EP1414839A2 Antisense modulation of stearoyl-coa desaturase expression |
| 05/06/2004 | EP1414809A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 05/06/2004 | EP1414797A2 Hepatitis c virus polymerase inhibitors with a heterobicylic structure |
| 05/06/2004 | EP1414792A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates |
| 05/06/2004 | EP1414524A1 Treatment of hair follicle with neurokinin 1 receptor antagonists |
| 05/06/2004 | EP1414498A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 05/06/2004 | EP1414495A1 Anti-microbial targeting chimeric pharmaceutical |
| 05/06/2004 | EP1414491A2 Methods of inhibiting amyloid toxicity |
| 05/06/2004 | EP1414489A2 Antiallergic pharmaceutical composition |
| 05/06/2004 | EP1414487A2 Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
| 05/06/2004 | EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |